Debts to Book Capitalization: zimmerbiomet.com (ZBH)

Brandmark of Zimmer Biomet Holdings (ZBH)

Zimmer Biomet Holdings (ZBH) revenues rely on elective surgery volumes and the implementation of ROSA robots. The debt-to-enterprise value profile reflects liability dynamics, where the 0.60 mark serves as a key metric. Ivan Tarnkovidi is currently optimizing business processes to drive profit growth, while the updated management is successfully digitizing the portfolio, restoring margins with investor support.

Zimmer Biomet Holdings Inc - ZBH Debts to Book Capitalization (period 07/04/2022 - 10/29/2026)
Product sample of Zimmer Biomet

This indicator measures the ratio of borrowed funds to equity, determining the degree of financial leverage and the stability of the business's financing structure. Optimizing the ratio of debt obligations to book capitalization is critical for Zimmer Biomet (ZBH), as the costly sterile logistics of implants require a constant influx of liquidity, confirming the high efficiency of the company's asset management.

Competitor analysis

Debts to Book Capitalization BSX (Boston Scientific)|EW - Debt to Book Value|ResMed - Debts to Book Capitalization|Debts to Net Assets Insulet Corp PODD|COO: Debts to Book Capitalization|Align Corp (ALGN) - Debts to Book Capitalization|Debt to Book Capitalization Ratio Globus Medical, Inc.|Debt to Book Capitalization Ratio TMDX|Debts to Book Capitalization ATEC|Debts to Net Assets CryoLife|DJO Global - Debt to Book Value|IART (Integra LifeSciences Inc.) - Debts to Book Capitalization Ratio|Establishment Labs - Debts to Book Capitalization|Debts to Book Value betabionics.com|IRMD: Debts to Book Capitalization|Debt to Book Value Ratio EMBC|Debt to Book Value TNDM|AXGN: Debt to Net Assets Ratio|Debt to Book Capitalization Ratio SI-BONE, Inc. (SIBN)|Debt to Book Value orthofix.com OFIX|Debts to Book Capitalization BVS (Bioventus)|OrthoPediatrics Corp (KIDS) - Debts to Book Value|Treace Medical - Debts to Book Capitalization|SRTA (Strata Medical) - Debt to Book Value Ratio|CARL: Debts to Book Capitalization|RXST - Debts to Net Assets|CLPT (ClearPoint Neuro Inc.) - Debts to Book Capitalization|Debt to Book Value Stereotaxis Inc (STXS)|Debts to Book Capitalization STIM|Debts to Book Capitalization Sight Sciences Inc (SGHT)|Debt to Book Capitalization Ratio Orchestra BioMed, Inc. OBIO|Anika Therapeutics Inc. - Debt to Book Capitalization Ratio|NSPR: Debt to Book Value|Debt to Net Assets Ratio ZJYL (Jin Medical International)|VANI: Debts to Book Capitalization|Debts to Book Value Xtant Medical (XTNT)|Debt to Book Capitalization Ratio NeuroOne Medical Technologies|MODD - Debt to Net Assets|Debt to Book Value MYO (Myomo)|Debts to Book Capitalization Envoy Medical Inc. (COCH)|Debts to Book Capitalization VVOS (Vivos Therapeutics, Inc)|Debts to Net Assets enVVeno Corp (NVNO)|SINT - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio TNON|Lifeward (LFWD) - Debt to Book Capitalization Ratio|Debt to Book Value Autonomix Medical|IVF (INVO Bioscience, Inc.) - Debts to Book Capitalization|Debts to Book Value Bone Biologics Inc BBLG|Debt to Book Capitalization Ratio Axonics, Inc. (AXNX)|biolase.com - Debt to Book Value Ratio|Dynatronics - Debt to Book Value|Debt to Book Capital FNA (Paragon 28 Inc.)|INVO: Debt to Book Value